Inhibitory FcγRIIb-mediated soluble antigen clearance from plasma by a pH-dependent antigen-binding antibody and its enhancement by Fc engineering

Journal of Immunology

Volumn 195, Issue 7, 2015, Pages 3198-3205

  Iwayanagi, Yuki ^a   Igawa, Tomoyuki ^a   Maeda, Atsuhiko ^a   Haraya, Kenta ^a   Wada, Naoko A ^a   Shibahara, Norihito ^a   Ohmine, Ken ^a   Nambu, Takeru ^a   Nakamura, Genki ^a   Mimoto, Futa ^a   Katada, Hitoshi ^a   Ito, Shunsuke ^a   Tachibana, Tatsuhiko ^a   Jishage, Kou Ichi ^a   Hattori, Kunihiro ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD16 ANTIGEN; FC RECEPTOR IIB; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G1 ANTIBODY; ANTIGEN; ANTIGEN ANTIBODY COMPLEX; FC RECEPTOR; FCGR2B PROTEIN, MOUSE; IMMUNOGLOBULIN G;

ANIMAL EXPERIMENT; ANTIBODY ENGINEERING; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CELL SURFACE; CONTROLLED STUDY; ENDOSOME; IN VIVO STUDY; INNATE IMMUNITY; INTERNALIZATION; MOUSE; NEWBORN; NONHUMAN; PH; PINOCYTOSIS; PLASMA CLEARANCE; PRIORITY JOURNAL; TRANSGENIC MOUSE; ANIMAL; ANTIGEN ANTIBODY REACTION; BLOOD; C57BL MOUSE; GENETICS; HUMAN; IMMUNOLOGY; KNOCKOUT MOUSE;

ANIMALS; ANTIBODIES; ANTIGEN-ANTIBODY COMPLEX; ANTIGEN-ANTIBODY REACTIONS; ANTIGENS; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, IGG;

EID: 84942446834     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1401470     Document Type: Article

References (34)

1. Clynes, R., Y. Takechi, Y. Moroi, A. Houghton, and J. V. Ravetch. 1998. Fc receptors are required in passive and active immunity to melanoma. Proc. Natl. Acad. Sci. USA 95: 652-656.
2. Clynes, R. A., T. L. Towers, L. G. Presta, and J. V. Ravetch. 2000. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6: 443-446.
3. Li, F., and J. V. Ravetch. 2012. Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcg receptor engagement. Proc. Natl. Acad. Sci. USA 109: 10966-10971.
4. Igawa, T., S. Ishii, T. Tachibana, A. Maeda, Y. Higuchi, S. Shimaoka, C. Moriyama, T. Watanabe, R. Takubo, Y. Doi, et al. 2010. Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat. Biotechnol. 28: 1203-1207.
5. Byrd, J. C., S. O'Brien, I. W. Flinn, T. J. Kipps, M. Weiss, K. Rai, T. S. Lin, J. Woodworth, D. Wynne, J. Reid, A. Molina, et al. 2007. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin. Cancer Res. 13: 4448-4455.
6. Davda, J. P., and R. J. Hansen. 2010. Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets. MAbs 2: 576-588.
7. Haringman, J. J., D. M. Gerlag, T. J. Smeets, D. Baeten, F. van den Bosch, B. Bresnihan, F. C. Breedveld, H. J. Dinant, F. Legay, H. Gram, et al. 2006. A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum. 54: 2387-2392.
8. Jayson, G. C., C. Mulatero, M. Ranson, J. Zweit, A. Jackson, L. Broughton, J. Wagstaff, L. Hakansson, G. Groenewegen, J. Lawrance, et al; European Organisation for Research and Treatment of Cancer (EORTC). 2005. Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer. Eur. J. Cancer 41: 555-563.
9. Martin, P. L., J. Cornacoff, U. Prabhakar, T. Lohr, G. Treacy, J. E. Sutherland, S. Hersey, and E. Martin. 2005. Reviews preclinical safety and immunemodulating effects of therapeutic monoclonal antibodies to interleukin-6 and tumor necrosis factor-a in cynomolgus macaques. J. Immunotoxicol. 1: 131-139.
10. Xiao, J. J., W. Krzyzanski, Y. M. Wang, H. Li, M. J. Rose, M. Ma, Y. Wu, B. Hinkle, and J. J. Perez-Ruixo. 2010. Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys. AAPS J. 12: 646-657.
11. Arend, W. P., and J. C. Sturge. 1979. Composition and biologic properties of soluble IgG-anti-IgG immune complexes: effects of variations in the specificity of rabbit antibodies to different structural components of human IgG. J. Immunol. 123: 447-454.
12. Benacerraf, B., M. Sebestyen, and N. S. Cooper. 1959. The clearance of antigen antibody complexes from the blood by the reticuloendothelial system. J. Immunol. 82: 131-137.
13. Ganesan, L. P., J. Kim, Y. Wu, S. Mohanty, G. S. Phillips, D. J. Birmingham, J. M. Robinson, and C. L. Anderson. 2012. FcgRIIb on liver sinusoidal endothelium clears small immune complexes. J. Immunol. 189: 4981-4988.
14. Kurlander, R. J., D. M. Ellison, and J. Hall. 1984. The blockade of Fc receptormediated clearance of immune complexes in vivo by a monoclonal antibody (2.4G2) directed against Fc receptors on murine leukocytes. J. Immunol. 133: 855-862.
15. Lukehart, S. A., M. R. Tam, J. Hom, S. A. Baker-Zander, K. K. Holmes, and R. C. Nowinski. 1985. Characterization of monoclonal antibodies to Treponema pallidum. J. Immunol. 134: 585-592.
16. Leabman, M. K., Y. G. Meng, R. F. Kelley, L. E. DeForge, K. J. Cowan, and S. Iyer. 2013. Effects of altered FcgR binding on antibody pharmacokinetics in cynomolgus monkeys. MAbs 5: 896-903.
17. Hand, P. H., B. Calvo, D. Milenic, T. Yokota, M. Finch, P. Snoy, K. Garmestani, O. Gansow, J. Schlom, and S. V. Kashmiri. 1992. Comparative biological properties of a recombinant chimeric anti-carcinoma mAb and a recombinant aglycosylated variant. Cancer Immunol. Immunother. 35: 165-174.
18. Igawa, T., A. Maeda, K. Haraya, T. Tachibana, Y. Iwayanagi, F. Mimoto, Y. Higuchi, S. Ishii, S. Tamba, N. Hironiwa, et al. 2013. Engineered monoclonal antibody with novel antigen-sweeping activity in vivo. PLoS One 8: e63236.
19. Dall'Acqua, W. F., R. M. Woods, E. S. Ward, S. R. Palaszynski, N. K. Patel, Y. A. Brewah, H. Wu, P. A. Kiener, and S. Langermann. 2002. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J. Immunol. 169: 5171-5180.
20. Richards, J. O., S. Karki, G. A. Lazar, H. Chen, W. Dang, and J. R. Desjarlais. 2008. Optimization of antibody binding to FcgRIIa enhances macrophage phagocytosis of tumor cells. Mol. Cancer Ther. 7: 2517-2527.
21. Roopenian, D. C., G. J. Christianson, and T. J. Sproule. 2010. Human FcRn transgenic mice for pharmacokinetic evaluation of therapeutic antibodies. Methods Mol. Biol. 602: 93-104.
22. Rashid, A., H. Auchincloss, Jr., and J. Sharon. 1992. Comparison of GK1.5 and chimeric rat/mouse GK1.5 anti-CD4 antibodies for prolongation of skin allograft survival and suppression of alloantibody production in mice. J. Immunol. 148: 1382-1388.
23. Nimmerjahn, F., and J. V. Ravetch. 2005. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science 310: 1510-1512.
24. Mimoto, F., H. Katada, S. Kadono, T. Igawa, T. Kuramochi, M. Muraoka, Y. Wada, K. Haraya, T. Miyazaki, and K. Hattori. 2013. Engineered antibody Fc variant with selectively enhanced FcgRIIb binding over both FcgRIIa(R131) and FcgRIIa(H131). Protein Eng. Des. Sel. 26: 589-598.
25. Bergtold, A., D. D. Desai, A. Gavhane, and R. Clynes. 2005. Cell surface recycling of internalized antigen permits dendritic cell priming of B cells. Immunity 23: 503-514.
26. Zhang, C. Y., and J. W. Booth. 2010. Divergent intracellular sorting of FcgRIIA and FcgRIIB2. J. Biol. Chem. 285: 34250-34258.
27. Weflen, A. W., N. Baier, Q. J. Tang, M. Van den Hof, R. S. Blumberg, W. I. Lencer, and R. H. Massol. 2013. Multivalent immune complexes divert FcRn to lysosomes by exclusion from recycling sorting tubules. Mol. Biol. Cell 24: 2398-2405.
28. Baker, K., S. W. Qiao, T. T. Kuo, V. G. Aveson, B. Platzer, J. T. Andersen, I. Sandlie, Z. Chen, C. de Haar, W. I. Lencer, et al. 2011. Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD82 CD11b+ dendritic cells. Proc. Natl. Acad. Sci. USA 108: 9927-9932.
29. Jefferis, R., and J. Lund. 2002. Interaction sites on human IgG-Fc for FcgR: current models. Immunol. Lett. 82: 57-65.
30. Lux, A., and F. Nimmerjahn. 2013. Of mice and men: the need for humanized mouse models to study human IgG activity in vivo. J. Clin. Immunol. 33(Suppl. 1): S4-S8.
31. Overdijk, M. B., S. Verploegen, A. Ortiz Buijsse, T. Vink, J. H. Leusen, W. K. Bleeker, and P. W. Parren. 2012. Crosstalk between human IgG isotypes and murine effector cells. J. Immunol. 189: 3430-3438.
32. Mimoto, F., S. Kadono, H. Katada, T. Igawa, T. Kamikawa, and K. Hattori. 2014. Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcgRs. Mol. Immunol. 58: 132-138.
33. Pollreisz, A., A. Assinger, S. Hacker, K. Hoetzenecker, W. Schmid, G. Lang, M. Wolfsberger, B. Steinlechner, E. Bielek, E. Lalla, et al. 2008. Intravenous immunoglobulins induce CD32-mediated platelet aggregation in vitro. Br. J. Dermatol. 159: 578-584.
34. Tomiyama, Y., T. J. Kunicki, T. F. Zipf, S. B. Ford, and R. H. Aster. 1992. Response of human platelets to activating monoclonal antibodies: importance of Fc gamma RII (CD32) phenotype and level of expression. Blood 80: 2261-2268.